HomeCompareEGRX vs QSR

EGRX vs QSR: Dividend Comparison 2026

EGRX yields 586.51% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EGRX wins by $215504.60M in total portfolio value
10 years
EGRX
EGRX
● Live price
586.51%
Share price
$0.34
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$215504.63M
Annual income
$161,378,417,110.69
Full EGRX calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — EGRX vs QSR

📍 EGRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEGRXQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EGRX + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EGRX pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EGRX
Annual income on $10K today (after 15% tax)
$49,853.37/yr
After 10yr DRIP, annual income (after tax)
$137,171,654,544.09/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, EGRX beats the other by $137,171,654,214.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EGRX + QSR for your $10,000?

EGRX: 50%QSR: 50%
100% QSR50/50100% EGRX
Portfolio after 10yr
$107752.33M
Annual income
$80,689,208,749.29/yr
Blended yield
74.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

EGRX
Analyst Ratings
2
Buy
3
Hold
1
Sell
Consensus: Hold
Altman Z
1.7
Piotroski
4/9
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.6% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EGRX buys
0
QSR buys
0
No recent congressional trades found for EGRX or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEGRXQSR
Forward yield586.51%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$215504.63M$24.7K
Annual income after 10y$161,378,417,110.69$387.88
Total dividends collected$210965.27M$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock
Analyst consensusHoldBuy

Year-by-year: EGRX vs QSR ($10,000, DRIP)

YearEGRX PortfolioEGRX Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$69,351$58,651.03$11,038$337.57+$58.3KEGRX
2$454,347$380,141.02$12,156$345.43+$442.2KEGRX
3$2,813,681$2,327,530.38$13,359$352.69+$2.80MEGRX
4$16,481,619$13,470,979.69$14,654$359.36+$16.47MEGRX
5$91,381,654$73,746,322.23$16,045$365.45+$91.37MEGRX
6$479,912,426$382,134,055.57$17,539$370.97+$479.89MEGRX
7$2,389,083,497$1,875,577,201.52$19,143$375.96+$2389.06MEGRX
8$11,282,425,682$8,726,106,340.14$20,863$380.42+$11282.40MEGRX
9$50,585,242,215$38,513,046,735.24$22,708$384.39+$50585.22MEGRX
10$215,504,626,280$161,378,417,110.69$24,685$387.88+$215504.60MEGRX

EGRX vs QSR: Complete Analysis 2026

EGRXStock

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Full EGRX Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this EGRX vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EGRX vs SCHDEGRX vs JEPIEGRX vs OEGRX vs KOEGRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.